Our Stocks to Watch tomorrow include Solos Endoscopy Inc. (OTC: SNDY), EcoSystem Corp. (OTCBB: ESYM), Red Branch Technologies Inc. (OTC: RBTI), Pansoft Company Ltd. (Nasdaq: PSOF), IntraOp Medical Corp. (OTCBB: IOPM) and Hythiam Inc. (Nasdaq: HYTM).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
SOLOS ENDOSCOPY INCORPORATED (OTC: SNDY)
"Up 181.25% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/SNDY.php
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office.
SNDY News:
September 17 - Solos Endoscopy, Inc. Receives Purchase Order from the National Cancer Institute
Solos Endoscopy, Inc. (OTC: SNDY) announced that the Company has received multiple purchase orders for its MammoView(TM) line of surgical endoscopy instruments from the National Cancer Institute (NCI), Bethesda MD. NCI is 1 of 27 Institutes and Centers that comprise the U.S. National Institutes of Health (NIH), which is part of the U.S. Department of Health and Human Services.
NCI has built a national network that includes regional and community cancer centers, physicians who are cancer specialists, cooperative groups of clinical researchers, and volunteer and community outreach groups throughout the
Solos Endoscopy's MammoView™ system employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts where the majority of breast cancers arise.
"We are very pleased to be supplying our MammoView system top cancer care and research organization in the world. We believe that our system will get well deserved exposure through the infrastructure NCI provides for basic, translational and clinical research activities encompassing all aspects of cancer, including biology, genetics, epidemiology, detection, diagnosis, treatment, prevention, palliative care and survivorship," stated Bob Segersten, President of Solos Endoscopy, Inc.
ECOSYSTEM CORPORATION (OTCBB: ESYM)
"Up 136.36% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/ESYM.php
EcoSystem’s ambition is to become a leading low-cost and low-carbon producer of renewable fuels by acquiring and upgrading existing corn ethanol facilities with technologies designed to increase the yield and to reduce the energy consumption and carbon intensity of refining fuel out of corn.
ESYM News:
August 7 - StockPreacher.com Issues Trading Outlook for EcoSystem Corp.
StockPreacher.com announces an investment report featuring EcoSystem Corp. (OTCBB: ESYM). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on EcoSystem Corp. (OTCBB: ESYM) should be of particular interest to farm products and alternative energy providers: Bunge Ltd. (NYSE: BG), Corn Products International Inc. (NYSE: CPO), Pacific Ethanol Inc. (Nasdaq: PEIX) and Green Plains Renewable
Energy Inc. (Nasdaq: GPRE).
It is available at www.stockpreacher.com/n/ESYM.
EcoSystem Corp. (ESYM) focuses on providing bioreactor technology for various industrial-scale applications. ESYM is developing technologies designed to increase the yield and reduce the energy and carbon intensity of traditional corn ethanol facilities. The Company intends to acquire and upgrade existing ethanol plants with its technologies, with a goal of becoming a leading low cost and low carbon producer of renewable fuels.
In the report, the analyst notes:
"The Company is specifically focused on the acquisition of distressed renewable fuel production assets, with an emphasis on first generation corn ethanol production facilities. ESYM is currently evaluating a number of qualified opportunities that produce the raw materials needed for its technologies, or that have the infrastructure it needs to scale the technologies, or that have the ability to refine the products that will be produced with its technologies into finished goods.
"The Company recently entered into a management services agreement with Global Ethanol LLC pursuant to which Global Ethanol LLC is expected to provide corporate and plant management services to the Company. Global Ethanol LLC operates two corn based ethanol plants for a production total of 160 MMGY located in
To read the entire report, visit www.stockpreacher.com/n/ESYM.
RED BRANCH TECHNOLOGIES INCORPORATED (OTC: RBTI)
"Up 62.50% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/RBTI.php
Red Branch Technologies, Inc., a technology holding company, engages in the development and commercialization of security and defense industry solutions. The company's my/mTravel and mTravel products automate the business travel process from planning and booking to route services and support, through post travel reporting and unused ticket redemption; and Magellan360 provides agency and net-delivered back office services to independent professional travel marketers. It also offers IdentiFlyer travel security services, which enable online transaction security by providing identity verification and authentication on a software as a service basis to online travel agencies. The company’s portfolio of representative products also includes security devices, robots, unmanned aerial vehicles, mobile power devices, and energy related products. Its solution portfolio focuses on various areas, including mobile security solutions, ordinance disposal and inspection, and aerial surveillance. The company was incorporated in 1987 and is based in
RBTI News:
September 18 - Red Branch Technologies to Offer Unique Set of Security Products
Red Branch Technologies, Inc. (OTC: RBTI) announced it is now offering a unique set of security products for military and law enforcement applications where cost and performance represent a critical selection factor. The security products cover a broad range of capabilities and price ranges to meet the needs of RBTI customers.
Red Branch offers several robotic solutions for security applications that range from under-vehicle standoff inspection to ordinance disposal to "hot site" emergency response. These products have wide ranging use for both military and law enforcement and industrial-security/safety organizations. In addition, UAVs represent the most complex and highly configurable security solutions available from Red Branch. Surveillance is the primary application and exceptional cost performance is their major competitive edge.
"Our products have a wide range of applications to meet the security needs of a number of targeted sectors," said Jeff Sirianni, CEO of Red Branch Technologies, Inc. "UAVs, for example, will be a major focus area when it comes to the future of aviation and the role it plays in providing an alternative security solution. We believe we are positioned to capture a piece of that market based on the unique set of security products we are offering at this time."
Red Branch's reactor model makes the company unique since it seeks to establish relationships among companies and partners within the reactor that accelerate and build reliable revenue growth. Powered by access to markets and combinations of product offerings within the reactor, RBTI succeeds from equity appreciation of the companies they power and by revenue derived from strategic relationships and major sales opportunities which they establish.
PANSOFT COMPANY LIMITED (NASDAQ: PSOF)
"Up 26.73% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/PSOF.php
Pansoft is a leading enterprise resource planning ("ERP") software and professional services provider for the oil and gas industry in
PSOF News:
September 18 - Pansoft and Microsoft Held Joint Press Conference 'ERP Innovation for Chinese Group Corporations' in
Pansoft Company Limited (NASDAQ: PSOF) announced that on September 17, 2009 in Beijing Pansoft held a successful joint press conference with Microsoft. Mr. Francis Sun, General Manager of the Greater China Region of Microsoft Business Solutions (MBS) and Mr. Guoqiang Lin, CEO of Pansoft, hosted the "ERP Innovation for Chinese Group Corporations" conference. There were more than 30 major media firms that attended the meeting.
Pansoft signed a Solution Provider Agreement (SPA) with Microsoft China, Co., Ltd. on May 11, 2009 to develop a centralized financial and accounting solution for Microsoft's Dynamics AX, a comprehensive ERP (Enterprise Resource Planning) system targeting large enterprises as well as growth Chinese corporations. After a short four months of diligent work, Pansoft's technical team successfully completed the project, which is now ready for the market debut. Pansoft is the only Chinese firm involved in the development of financial system for Dynamics AX. It was chosen to be the alliance partner with Microsoft given Pansoft's enormous success in developing a Centralized Financial and Accounting System for PetroChina. That solution was highly praised by Mr. Jun Wang,
Pansoft leveraged the concept from PetroChina's solution and developed the program for Dynamics AX to enhance the centralized financial and accounting function. Mr. Sun, General Manager of MBS said, "Microsoft strives to bring the best global managerial experiences to Chinese corporations. We are pleased to be the partner with Pansoft, a company with extensive experience in corporate financial management. We can complement each other's strengths to provide the best solutions for our clients."
Microsoft has superior brand recognition as well as broad sales and distribution channels globally. Pansoft's partnership with Microsoft adds additional sales venue to the company's products and solutions. In addition, it should increase Pansoft's own brand awareness. More importantly, as Dynamics AX is marketing to Chinese group corporations in various industries, it should help Pansoft enter other markets beyond oil and gas. This fits in with Pansoft's business development strategy.
Mr. Lin, CEO of Pansoft, commented, "Chinese enterprises' background histories, cultural and management habits and regional characteristics all add difficulties to ERP system implementations in
INTRAOP MEDICAL CORPORATION (OTCBB: IOPM)
"Up 16.41% on Friday"
Detailed Quote: www.otcpicks.com/quotes/IOPM.php
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively — for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, immediate palliative effect, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics world-wide are increasingly using the Mobetron to treat a wide variety of cancers as a vital part of their comprehensive cancer program.
IOPM News:
September 15 - Groundbreaking Breast Cancer Radiation Technique Delivers Proven Long-Term Benefits and Saves Lives
One minute of radiation in the operating room (OR) could save the lives of thousands of women being treated for breast cancer in the
Now, a portable, self-contained radiation therapy system, the Mobetron from IntraOp Medical Corporation (OTCBB: IOPM) in
Felix Sedlmayer, MD, one of the world’s leading IOERT researchers and the principal investigator of IOERT boost trials conducted by six European medical centers over the past decade, concluded that IOERT cut breast cancer five year recurrence rates dramatically, from an average of 5% to less than 1%.
“If the IOERT boost were a standard technique in the US, every year, more than 5000 breast cancer recurrences could have be avoided,” according to Roland Reitsamer, MD, a surgeon at the University of Salzburg, where the technique has been studied extensively for the past decade. Each one of those recurrences typically would result in a subsequent mastectomy, which also would be avoided. A prestigious Lancet review of studies on breast cancer found a 25% increase in 15 year survival for patients with no recurrences at five years, suggesting that IOERT boost could have a significant impact on the survival of thousands of women worldwide.
What Every Woman Should Know About Intraoperative Radiation
It seems a matter of common sense. Lumpectomy is typically followed by a six-week course of radiation therapy to help eliminate any remaining malignant cells. Treatment takes place at least four weeks after surgery when the breast has healed. Because traditional, post-operative radiation is delivered externally, it must pass through the body to reach diseased areas, and healthy tissue may be damaged in the process. Additionally, once surgery is complete, physicians no longer have direct access to the target area to easily and precisely deliver radiation.
So why not begin the radiation treatment during the surgery itself? This would immediately target any remaining cancer cells, while allowing complete access to the tumor area for greater precision in radiation delivery. It also would spare radiation dose to surrounding tissue and reduce the number of days a woman has to travel to a cancer center for external treatment after surgery. In fact, at
“The answer is that intraoperative radiation simply hasn’t been practical until now,” explains John Powers, CEO for IntraOp. ”Without the Mobetron, the treatment would mean equipping a special operating room with a costly, unwieldy 18,000 pound linear accelerator to generate radiation as well as a shielded radiation vault to protect staff from repeated exposure to this radiation. This is just not feasible for most hospitals.”
The other alternative, Mr. Powers points out, has been transferring patients under anesthesia with an open incision from the OR to a radiation therapy center, typically located offsite. This significantly increases the risk and duration of surgery and anesthesia. The result: despite its enormous benefits, IOERT has rarely been used in the
However, IOERT has been heavily investigated in major European university hospitals and is currently in use in more than a dozen facilities. This is not surprising because historically the European medical system has been an early adopter of promising new paradigms for breast cancer diagnosis and treatment, including mammography, breast conserving lumpectomy and sentinel node biopsy.
The Mobetron
Specifically optimized for IOERT, the IntraOp Mobetron incorporates a range of technological innovations to make all the benefits of this treatment realistic and practical for women and their doctors around the world. The innovative system eliminates the risk, time, cost and complexity of IOERT by enabling delivery in any standard OR.
Unlike conventional linear accelerators, the Mobetron is relatively lightweight and can be wheeled among different OR locations. The Mobetron requires no external radiation vault or bunker because patented technologies eliminate most stray room radiation generated by conventional accelerators and because of its patented self-shielding,
To operate the device, following tumor excision, a Mobetron applicator tube is temporarily inserted into the breast to provide precise treatment directly to the tumor bed. The Mobetron is positioned for radiation delivery, and the one-minute treatment takes place.
HYTHIAM INCORPORATED (NASDAQ: HYTM)
"Up 9.41% in after hours trading on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/HYTM.php
Hythiam, Inc. provides through its Catasys subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys substance dependence program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary PROMETA® Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA Treatment Program.
HYTM News:
September 17 - Hythiam Enters into Agreement with Ford Motor Company for Catasys Integrated Substance Dependence Solution
Hythiam, Inc. (Nasdaq: HYTM) announced that the Company has entered into a three year agreement with Ford® Motor Company to provide the Catasys® integrated substance dependence solution to Ford’s hourly employees in Michigan enrolled in the National PPO and who meet certain criteria. Eligible employees struggling with alcoholism, stimulant and opiate dependence will be covered under the program, which contains medical interventions including naltrexone, Suboxone® and the proprietary PROMETA® Treatment Program, and psychosocial and care coaching components across 52 weeks. The Company will conduct direct outreach to enroll qualified members, and will also work with UAW-Ford and Ford’s EAP program to ensure the most beneficial treatment pathway for members. Contractual revenues from the agreement are based on a combination of monthly fees for the member population for Catasys, with additional monthly fees for members enrolled into the Catasys program. Operational implementation is expected to begin shortly, and the program is anticipated to launch in the fourth quarter of 2009.
“We are pleased by the level of support we received from UAW-Ford and Ford’s management personnel,” said Terren Peizer, Hythiam’s Chairman and CEO. “Our ability to engage and contract with employers and health plans highlights the flexibility of our program to address substance dependence challenges faced by diverse payors and their member populations. We have realigned our company and developed Catasys for the managed care market, and it is rewarding to have a new agreement that further publicly validates our product and business model. Ford’s desire to improve employee care and productivity demonstrates a significant opportunity for health plans to provide their customers the Catasys solution. We look forward to additional agreements over the coming months, and we remain focused on providing effective solutions that enhance member care and improve clinical outcomes, resulting in lower total health care costs. This is especially important as payors face multiple challenges including the recently passed mental health parity and addiction equity bill (Wellstone Domenici Mental Health Parity and Addiction Equity Act of 2008), and increasing budgetary constraints at a time of rising substance dependence rates due to the current economic environment.”
Various studies, research and other resources demonstrate that:
* Problems related to alcohol and drug abuse cost American businesses roughly $81 billion in lost productivity each year.
* 77% of illicit drug users in the
* 500 million workdays are lost annually due to alcoholism.
* Up to 40% of industrial fatalities and 47% of industrial injuries can be linked to alcohol use and alcoholism.
* Employees who use drugs are 3.6 times more likely to be involved in a workplace accident and 5 times more likely to file a workers’ compensation claim.
* Employees who use drugs are 2.2 times more likely to request early dismissal or time off, 2.5 times more likely to have absences of eight days or more, and 3 times more likely to be late for work.
Catasys is focused on improving member care and providing better clinical outcomes in an effort to reduce overall health care costs. Catasys was designed to manage substance dependence as a chronic disease, with a focus on integration between evidence-based medical and psychosocial elements in an outpatient setting, combined with care coaches who will guide and assist members with long-term recovery. Catasys includes identification, engagement, treatment, coaching and ongoing monitoring components directed at providing members with a customized pathway to recovery. The delivery of the program’s medical and psychosocial components is conducted by a trained specialty network of providers who are addiction specialists, and who organize care with care coaches through Catasys’s IT technology platform. Catasys also conducts outreach to qualified members and coordinates with client resources to enroll them in the program, including a focus on reducing barriers to treatment.
ABOUT HYTHIAM® AND CATASYS®
Hythiam, Inc. provides through its Catasys subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys substance dependence program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary PROMETA® Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA Treatment Program.
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.
